Mark your calendars for Tuesday 29th October 2024, as Utah Medical Products (NASDAQ: UTMD) will be revealing its third quarter financial results. This highly awaited announcement is scheduled to take place before market open, pave the way to review a period of expectation and anticipation.
In the corresponding quarter of the previous year, the company's earnings report unveiled a per-share income of $1.08. Notably, the company's total revenue reached an impressive $12.51 million during that specific period.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $0.98 | -14.8% | 10.40 M | -19.2% |
| Q1 2024 | $1.09 | -6.0% | 11.34 M | -9.4% |
| Q4 2023 | $1.18 | -5.6% | 12.33 M | -9.1% |
| Q3 2023 | $1.08 | -8.5% | 12.51 M | -3.5% |
| Q2 2023 | $1.15 | +2.7% | 12.87 M | -4.2% |
| *Growth on year-over-year basis | ||||
Utah Medical Products (UTMD) shares traded as low as $63.86 and as high as $64.71 on a day volume of 50.50 thousand shares, closed Friday's regular trading session at $64.12, decline of 0.26 percent.
